Search

Veracyte Inc

Gesloten

SectorGezondheidszorg

56.48 -2.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

56.04

Max

57.91

Belangrijke statistieken

By Trading Economics

Inkomsten

-20M

29M

Verkoop

-1.6M

139M

K/W

Sectorgemiddelde

54.533

62.58

EPS

0.52

Winstmarge

20.642

Werknemers

755

EBITDA

-11M

35M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+1.94% upside

Dividenden

By Acuity

Volgende Winsten

30 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.9B

4.6B

Vorige openingsprijs

58.7

Vorige sluitingsprijs

56.48

Nieuwssentiment

By Acuity

50%

50%

163 / 340 Rangschikking in Healthcare

Veracyte Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22 jul 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 jul 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20 jul 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Peer Vergelijking

Prijswijziging

Veracyte Inc Prognose

Koersdoel

By TipRanks

1.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 59 USD  1.94%

Hoogste 70 USD

Laagste 47 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Veracyte Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

8

Buy

1

Hold

1

Sell

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat